ClinicalTrials.gg
CompletedNCT03524092LUCENT 2Updated May 13, 2026Results posted

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Mirikizumab SC and Mirikizumab IV in Ulcerative Colitis, sponsored by Eli Lilly and Company. Completed at 385 sites in 34 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,328
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
Largest of 13
1,328 · median 172
Started
2018
with 2 others
Phase 3
7 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one has the largest enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 4th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Interleukin-23 (IL-23)
  • IL-23p19
  • Inflammatory Bowel Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug.
  • Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
  • If female, must meet the requirements.

Exclusion criteria

Exclusion Criteria:

  • Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086).
  • Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG.
  • Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086).
  • Participants diagnosed with infection including, but not limited to, , , /AIDS, and active tuberculosis (TB) during the induction study AMAN (NCT03518086).
  • Participants who initiate a new prohibited medication during the induction study AMAN (NCT03518086).
  • Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,328 participants (actual)

Study arms

  • Placebo comparator
    Maintenance Period: Miri Induction Responder (IR) - Placebo (PBO) Subcutaneous (SC)

    Participants who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.

    Drug: Placebo SC

  • Experimental
    Maintenance Period: Miri IR - 200 Milligram (mg) Miri SC

    Participants who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.

    Drug: Mirikizumab SC

  • Experimental
    Maintenance Period: PBO IR - PBO SC

    Participants who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.

    Drug: Placebo SC

  • Experimental
    Maintenance Period: Miri IR - PBO SC - ME2 Cohort

    Participants in the ME2 Cohort who were responders to blinded mirikizumab (miri) at Week 12 in induction study (LUCENT-1) randomized to withdraw from mirikizumab and start receiving PBO SC every 4 weeks (Q4W) from Week 0 of maintenance study (LUCENT-2) until Week 40 or until loss of response was confirmed.

    Drug: Placebo SC

  • Experimental
    Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort

    Participants in the ME2 Cohort who were responders to blinded mirikizumab at Week 12 in induction study (LUCENT-1) randomized to continue to receive 200 mg mirikizumab SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.

    Drug: Mirikizumab SC

  • Experimental
    Maintenance Period: PBO IR - PBO SC - ME2 Cohort

    Participants in the ME2 Cohort who were responders to blinded placebo at Week 12 in induction study (LUCENT-1) continue to receive blinded placebo SC Q4W from Week 0 of LUCENT-2 until Week 40 or until loss of response was confirmed.

    Drug: Mirikizumab IV · Drug: Placebo SC

  • Experimental
    Loss of Response (LOR) Rescue Period: LOR Cohort-300 mg Miri IV

    Participants who received blinded PBO SC or blinded 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.

    Drug: Mirikizumab IV

  • Experimental
    LOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 Cohort

    Participants in the ME2 Cohort who received blinded PBO SC or blinded 200 mg mirikizumab SC Q4W during maintenance period and experienced a loss of response at or after Week 12, received rescue therapy with open label 300 mg mirikizumab intravenous (IV) Q4W for 3 doses.

    Drug: Mirikizumab IV

  • Experimental
    Extended Induction: Induction Nonresponders - 300mg Miri IV

    Participants who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.

    Drug: Mirikizumab IV

  • Experimental
    Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort

    Participants in the ME2 Cohort who were nonresponders to blinded mirikizumab or placebo in induction study (LUCENT-1), received additional 3 doses of open label 300 mg mirikizumab IV Q4W during extended induction period from Week 0 of LUCENT-2 until Week 12.

    Drug: Mirikizumab IV

  • Experimental
    Open Label Maintenance: Delayed Responders - 200 mg Miri SC

    Participants who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40 or until early termination (rescue was not available for these participants).

    Drug: Mirikizumab SC

  • Experimental
    Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort

    Participants in the ME2 Cohort who initially did not respond to induction study (LUCENT-1), but responded to extended induction therapy at Week 12 of LUCENT-2 (delayed responders), received 200 mg mirikizumab SC Q4W during open label maintenance period from Week 12 until Week 40 or until early termination (rescue was not available for these participants).

    Drug: Mirikizumab SC

Interventions

  • Administered SC

    Also known as: LY3074828

  • Administered IV

    Also known as: LY3074828

  • DrugPlacebo SC

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

    Clinical remission at week 40 is defined as achieving a 9-point modified Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); Endoscopy Subscore, based on central reading of colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). Modified Intention-to-treat population (mITT): All randomized participants who received at least one dose of mirikizumab and who had a correctly measured Modified Mayo Score at baseline. Participants were analyzed according to the treatment arm to which they were randomized, regardless of the treatment actually received.

    Time frame: Week 40

Secondary outcomes

  1. Percentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders)

    Endoscopic remission at week 40 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 40. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).

    Time frame: Week 40

  2. Percentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders)

    Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).

    Time frame: Week 40

  3. Percentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders)

    Symptomatic remission at week 40 is defined as a Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).

    Time frame: Week 40

  4. Percentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders)

    Endoscopic response at week 40 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore.

    Time frame: Week 40

  5. Percentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders)

    Clinical response at week 40 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).

    Time frame: Week 40

  6. Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders)

    The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).

    Time frame: Induction Baseline, Week 40

  7. Change From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders)

    Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using ANCOVA model for post-baseline measures: The ANCOVA model includes treatment, baseline value, prior biologic or tofacitinib failure (yes/no), corticosteroid use (yes/no) at AMAN baseline, region (North America/Europe/Other), Clinical Remission status (yes/no) at AMAN Week 12.

    Time frame: Induction Baseline, Week 40

  8. Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders)

    The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).

    Time frame: Induction Baseline, Week 40

  9. Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders)

    Percentage of participants hospitalized for UC. Only hospitalizations associated with an adverse event with \>=24 hours stay were recorded.

    Time frame: Week 40

  10. Pharmacokinetics (PK): Clearance of Mirikizumab

    Clearance of mirikizumab was evaluated.

    Time frame: Predose: Weeks 0, 4, 12, 24 and 40

07

Results

Posted Nov 25, 2022

Participant flow

A total of 1177 Participants (pts) enrolled in study of which 716 pts entered to Blinded Maintenance Period as Induction Responder (IR) and 461 pts entered into open label extended Induction period as Induction Nonresponders. This LUCENT-2 (I6T-MC-AMBG, NCT03524092) study was designed to evaluate safety and efficacy of mirikizumab (miri) in achieving remission at Week (Wk) 40 in pts who completed the 12-wk induction study LUCENT-1 (I6T-MC-AMAN,NCT03518086) as clinical responders to mirikizumab.

Blinded Maintenance Period (Wk 0-40)
Participant flow — Blinded Maintenance Period (Wk 0-40)
MilestoneMaintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC)Maintenance Period: Miri IR - 200 Milligram (mg) Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLoss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IVLOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Started192389135215212000000
Received at least one dose of study drug192389135215212000000
Completed1193479012468000000
Not completed734245964000000
Withdrew: Adverse event1661240000000
Withdrew: Lack of efficacy867000000000
Withdrew: Lost to follow-up010000000000
Withdrew: Physician decision010000000000
Withdrew: Pregnancy001000000000
Withdrew: Protocol violation011000000000
Withdrew: Withdrawal by subject786100000000
Withdrew: Loss of response rescue period421929624000000
Loss of Response Rescue Period
Participant flow — Loss of Response Rescue Period
MilestoneMaintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC)Maintenance Period: Miri IR - 200 Milligram (mg) Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLoss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IVLOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Started00000090120000
Completed0000008190000
Not completed000000930000
Withdrew: Adverse event000000200000
Withdrew: Lack of efficacy000000510000
Withdrew: Pregnancy000000100000
Withdrew: Withdrawal by subject000000100000
Withdrew: Completed rescue treatment and rolled over to study i6t-mc-amap (nct03519945)000000020000
Open Label Extended Induction (Wk 0-12)
Participant flow — Open Label Extended Induction (Wk 0-12)
MilestoneMaintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC)Maintenance Period: Miri IR - 200 Milligram (mg) Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLoss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IVLOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Started000000004616600
Completed000000002713300
Not completed000000001903300
Withdrew: Adverse event0000000011100
Withdrew: Covid-19 related study disruption000000004000
Withdrew: Lack of efficacy000000001622600
Withdrew: Physician decision000000001000
Withdrew: Protocol violation000000005100
Withdrew: Withdrawal by subject000000006500
Withdrew: Lack of capacity due to lack of staff000000001000
Open Label Maintenance Period (Wk 12-40)
Participant flow — Open Label Maintenance Period (Wk 12-40)
MilestoneMaintenance Period: Miri IR - Placebo (PBO) Subcutaneous (SC)Maintenance Period: Miri IR - 200 Milligram (mg) Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLoss of Response (LOR) Rescue Period:LOR Cohort-300 mg Miri IVLOR Rescue Period:LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Started000000000027133
Completed000000000025630
Not completed0000000000153
Withdrew: Adverse event000000000041
Withdrew: Covid-19 related study disruption000000000010
Withdrew: Lack of efficacy000000000090
Withdrew: Protocol violation000000000010
Withdrew: Withdrawal by subject000000000002

Outcome measures

PrimaryPercentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

Clinical remission at week 40 is defined as achieving a 9-point modified Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline, and endoscopy=0 or 1 (excluding friability). Stool Frequency Subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal Bleeding Subscore, based on the participant's diary and scored from 0 (no blood) to 3 (blood only passed); Endoscopy Subscore, based on central reading of colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). Modified Intention-to-treat population (mITT): All randomized participants who received at least one dose of mirikizumab and who had a correctly measured Modified Mayo Score at baseline. Participants were analyzed according to the treatment arm to which they were randomized, regardless of the treatment actually received.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)25.1 (18.8 to 31.5)49.9 (44.7 to 55.0)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 23.2 · 95% CI 15.2 to 31.2
SecondaryPercentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders)

Endoscopic remission at week 40 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 40. Endoscopy subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants in Endoscopic Remission at Week 40 (Mirikizumab Induction Responders)29.1 (22.4 to 35.7)58.6 (53.6 to 63.7)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 28.5 · 95% CI 20.2 to 36.8
SecondaryPercentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders)

Histologic remission was assessed using the Geboes histologic scoring system developed for assessment of histologic disease activity in ulcerative colitis. Remission was defined as Geboes histological subscore of 0 for grades: 2b (lamina propria neutrophils), and 3 (neutrophils in epithelium), and 4 (crypt destruction), and 5 (erosion or ulceration).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants With Histologic Remission at Week 40 (Mirikizumab Induction Responders)24.6 (18.3 to 30.9)48.5 (43.4 to 53.6)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 22.5 · 95% CI 14.5 to 30.5
SecondaryPercentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders)

Symptomatic remission at week 40 is defined as a Mayo score for rectal bleeding=0, stool frequency=0 or 1 with ≥ 1 point decrease from baseline. Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal). Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants in Symptomatic Remission at Week 40 (Mirikizumab Induction Responders)39.7 (32.5 to 46.8)71.0 (66.3 to 75.6)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 30.2 · 95% CI 21.9 to 38.6
SecondaryPercentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders)

Endoscopic response at week 40 is defined as achieving at least a 1 point decrease from baseline in the Mayo endoscopic subscore.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants in Endoscopic Response at Week 40 (Mirikizumab Induction Responders)40.8 (33.6 to 48.0)72.6 (68.0 to 77.2)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 31.0 · 95% CI 22.4 to 39.6
SecondaryPercentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders)

Clinical response at week 40 is defined as a decrease in the 9-point modified Mayo score (MMS) \[rectal bleeding, stool frequency and the endoscopic findings\] inclusive of \>= 2 points and \>=30% from baseline with either a decrease of rectal bleeding subscore of \>=1 or rectal bleeding subscore of 0 or 1.The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: Stool frequency subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); Rectal bleeding subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); Endoscopy subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration).

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants in Clinical Response at Week 40 (Mirikizumab Induction Responders)49.2 (41.8 to 56.5)80.3 (76.2 to 84.4)
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 30.6 · 95% CI 22.3 to 38.9
SecondaryChange From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders)

The IBDQ is a 32-item participant-completed questionnaire that measures 4 aspects of subjects' lives: symptoms directly related to the primary bowel disturbance, systemic symptoms, emotional function, and social function. Responses are graded on a 7-point. Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." Scores range from 32 to 224; a higher score indicates a better quality of life. Least square (LS) Mean was calculated using analysis of covariance (ANCOVA) model for post-baseline measures: The ANCOVA model includes: treatment, baseline value, prior biologic or tofacitinib failure (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).

Time frame:
Induction Baseline, Week 40
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders)
score on a scaleMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Change From Baseline to Week 40 in Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Mirikizumab Induction Responders)24.51 ± 2.76749.75 ± 2.102
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · ANCOVA · p = <0.001 · Ls mean difference (final values): 25.24 · 95% CI 19.16 to 31.32ANCOVA with modified baseline observation carried forward (mBOCF).
SecondaryChange From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders)

Fecal calprotectin is an indicator of inflammation in the colon with higher levels indicative of higher levels of inflammation. Least square (LS) Mean was calculated using ANCOVA model for post-baseline measures: The ANCOVA model includes treatment, baseline value, prior biologic or tofacitinib failure (yes/no), corticosteroid use (yes/no) at AMAN baseline, region (North America/Europe/Other), Clinical Remission status (yes/no) at AMAN Week 12.

Time frame:
Induction Baseline, Week 40
Reported as:
Least squares mean · milligram per kilogram (mg/kg)
Change From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders)
milligram per kilogram (mg/kg)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Change From Baseline to Week 40 in Fecal Calprotectin (Mirikizumab Induction Responders)-1155.82 ± 221.394-1995.47 ± 172.443
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · ANCOVA · p = <0.001 · Ls mean difference (final values): -839.64 · 95% CI -1323.08 to -356.21ANCOVA with modified baseline observation carried forward (mBOCF).
SecondaryChange From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders)

The Urgency NRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Least square (LS) Mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: The MMRM model includes treatment, baseline value, visit, interaction of baseline value-by-visit, interaction of treatment-by-visit, prior biologic or tofacitinib failure (yes/no), baseline corticosteroid use (yes/no), clinical remission status (yes/no) at AMAN Week 12, and region (North America/Europe/Other).

Time frame:
Induction Baseline, Week 40
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders)
score on a scaleMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Change From Baseline to Week 40 in Bowel Urgency Based on the Urgency Numeric Rating Scale (NRS) (Mirikizumab Induction Responders)-2.74 ± 0.202-3.80 ± 0.139
Statistical analysis
  • Maintenance Period: Miri IR - PBO SC vs Maintenance Period: Miri IR - 200 mg Miri SC · Mixed Models Analysis · p = <0.001 · Ls mean difference (final values): -1.06 · 95% CI -1.51 to -0.61
SecondaryPercentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders)

Percentage of participants hospitalized for UC. Only hospitalizations associated with an adverse event with \>=24 hours stay were recorded.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders)
percentage of participantsMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SC
Percentage of Participants Hospitalized for Ulcerative Colitis (UC) (Mirikizumab Induction Responders)1.10
SecondaryPharmacokinetics (PK): Clearance of Mirikizumab

Clearance of mirikizumab was evaluated.

Time frame:
Predose: Weeks 0, 4, 12, 24 and 40
Reported as:
Geometric mean · Liters per Hour (L/h)
Pharmacokinetics (PK): Clearance of Mirikizumab
Liters per Hour (L/h)200 Milligram (mg) Miri SC
Pharmacokinetics (PK): Clearance of Mirikizumab0.0487 ± 54

Adverse events

Collected over Baseline Up to week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maintenance Period: Miri IR - PBO SC1/192 (0.5%)16/192 (8.3%)82/192 (42.7%)
Maintenance Period: Miri IR - 200 mg Miri SC0/389 (0%)13/389 (3.3%)143/389 (36.8%)
Maintenance Period: PBO IR - PBO SC0/135 (0%)8/135 (5.9%)58/135 (43%)
Maintenance Period: Miri IR - PBO SC - ME2 Cohort0/21 (0%)4/21 (19%)16/21 (76.2%)
Maintenance Period: Miri IR - 200 mg Miri SC - ME2 Cohort0/52 (0%)7/52 (13.5%)32/52 (61.5%)
Maintenance Period: PBO IR - PBO SC - ME2 Cohort0/12 (0%)1/12 (8.3%)10/12 (83.3%)
LOR Rescue Period: LOR Cohort-300 mg Miri IV0/90 (0%)3/90 (3.3%)18/90 (20%)
LOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 Cohort0/12 (0%)2/12 (16.7%)4/12 (33.3%)
Extended Induction: Induction Nonresponders - 300mg Miri IV0/461 (0%)24/461 (5.2%)74/461 (16.1%)
Extended Induction: Induction Nonresponders - 300mg Miri IV - ME2 Cohort0/66 (0%)4/66 (6.1%)22/66 (33.3%)
Open Label Maintenance: Delayed Responders - 200 mg Miri SC0/271 (0%)9/271 (3.3%)91/271 (33.6%)
Open Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort0/33 (0%)3/33 (9.1%)13/33 (39.4%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLOR Rescue Period: LOR Cohort-300 mg Miri IVLOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Colitis ulcerativeGastrointestinal disorders7/1920/3891/1351/211/520/121/901/129/4612/663/2712/33
Ankle fractureInjury, poisoning and procedural complications0/1920/3890/1350/210/521/120/900/120/4610/660/2710/33
Colorectal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1920/3890/1350/210/520/120/901/120/4610/660/2710/33
Inguinal herniaGastrointestinal disorders0/1921/3890/1351/210/520/120/900/120/4610/660/2710/33
Clostridium difficile infectionInfections and infestations0/1920/3890/1351/210/520/120/900/120/4610/660/2710/33
HeadacheNervous system disorders0/1920/3890/1351/210/520/120/900/120/4610/660/2710/33
Anal abscessInfections and infestations0/1920/3890/1350/210/520/120/900/120/4610/660/2711/33
Human chorionic gonadotropin increasedInvestigations0/1920/3890/1350/210/520/120/900/120/4610/660/2711/33
UreterolithiasisRenal and urinary disorders0/1920/3890/1350/210/520/120/900/121/4610/660/2711/33
GastritisGastrointestinal disorders0/1920/3890/1350/211/520/120/900/120/4610/660/2710/33
Most frequent other events
Showing 10 of 43
Most frequent other events
EventMaintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortLOR Rescue Period: LOR Cohort-300 mg Miri IVLOR Rescue Period: LOR Cohort-300 mg Miri IV - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortOpen Label Maintenance: Delayed Responders - 200 mg Miri SCOpen Label Maintenance: Delayed Responders - 200 mg Miri SC - ME2 Cohort
Colitis ulcerativeGastrointestinal disorders35/19226/38917/1356/214/523/120/900/124/4611/6610/2711/33
Upper respiratory tract infectionInfections and infestations5/1927/3892/1354/218/521/121/900/123/4616/669/2714/33
AnaemiaBlood and lymphatic system disorders9/1928/3898/1353/212/522/125/900/127/4614/669/2711/33
Covid-19Infections and infestations4/1928/3895/1353/216/521/121/901/124/4614/666/2711/33
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/780/1600/610/60/230/50/430/70/1660/180/1111/7
Clostridium difficile infectionInfections and infestations3/1921/3891/1352/210/520/122/900/124/4613/663/2711/33
Alanine aminotransferase increasedInvestigations1/1924/3891/1352/211/520/121/900/120/4612/660/2710/33
Aspartate aminotransferase increasedInvestigations0/1923/3890/1352/211/520/121/900/121/4611/661/2710/33
HypoalbuminaemiaMetabolism and nutrition disorders0/1920/3890/1352/211/520/120/901/120/4610/660/2710/33
HypokalaemiaMetabolism and nutrition disorders0/1922/3890/1352/210/521/121/900/121/4614/660/2711/33

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortTotal
Mean41.20 ± 12.8843.30 ± 14.1340.80 ± 13.4049.10 ± 10.7142.50 ± 13.9056.20 ± 14.0143.40 ± 13.8644.40 ± 14.8243.0 ± 13.85
Sex: Female, Male
Sex: Female, Male(Participants)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortTotal
Female7816061623516618517
Male114229741529729548811
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortTotal
Hispanic or Latino212200011027
Not Hispanic or Latino18338000530112
Unknown or Not Reported172344125215212397661189
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortTotal
American Indian or Alaska Native1320004010
Asian5193282152128766410
Native Hawaiian or Other Pacific Islander000000101
Black or African American0600006012
White1382851030003580884
More than one race002000103
Unknown or Not Reported220000408
Region of Enrollment
Region of Enrollment(Participants)Maintenance Period: Miri IR - PBO SCMaintenance Period: Miri IR - 200 mg Miri SCMaintenance Period: PBO IR - PBO SCMaintenance Period: Miri IR - PBO SC - ME2 CohortMaintenance Period: Miri IR - 200 mg Miri SC - ME2 CohortMaintenance Period: PBO IR - PBO SC - ME2 CohortExtended Induction: Induction Nonresponders - 300mg Miri IVExtended Induction: Induction Nonresponders - 300mg Miri IV - ME2 CohortTotal
China341215212766166
Argentina1500005011
Australia0300009012
Austria220000408
Belgium122000409
Canada35200021031
Czechia7191100015052
Denmark330000107
France1018600023057
Germany513300016037
Hungary18200012023
India18251600013072
Ireland010000001
Israel3610005015
Italy312400017036
Japan25478000430123
Latvia81030008029
Lithuania6450007022
Malaysia030000306
Mexico1320004010
Netherlands1600003010
Poland153213000620122
Romania4200008014
Russia193616000290100
Serbia1940007021
Slovakia6710007021
South Korea38100013025
Spain1640009020
Switzerland0400006010
Taiwan110000103
Turkey052000108
Ukraine18311600028093
United Kingdom2420006014
United States214510000640140
08

Study locations

385 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Dcr-Pi, Pc
    Litchfield Park, Arizona 85340, United States
  • Maricopa Integrated Health System
    Phoenix, Arizona 85008, United States
  • Physicians Research Group
    Tempe, Arizona 85284, United States
  • Valley Gastroenterology
    Arcadia, California 91006, United States
  • Care Access Research
    Berkeley, California 94705, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • California Medical Research Associates
    Northridge, California 91324, United States
  • Clinical Applications Laboratories, Inc.
    San Diego, California 92103, United States
  • UCSF Medical Center at Mission Bay
    San Francisco, California 94158, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 34452, United States
  • SIH Research, LLC
    Kissimmee, Florida 34741, United States
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
  • Wellness Clinical Research
    Miami Lakes, Florida 33016, United States
  • Center for Interventional Endoscopy
    Orlando, Florida 32803, United States
  • Clintheory Healthcare
    Orlando, Florida 32818, United States
  • Gastroenterology Associates of Pensacola, PA
    Pensacola, Florida 32503, United States
  • Florida Medical Clinic LLC
    Zephyrhills, Florida 33542-7505, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Grand Teton Research Group
    Idaho Falls, Idaho 83404, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Texas Digestive Disease Consultants
    Baton Rouge, Louisiana 70809, United States
  • Delta Research Partners LLC
    Monroe, Louisiana 71201, United States
  • Nola Research Works, LLC
    New Orleans, Louisiana 70125, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Huron Gastroenterology Associates
    Ypsilanti, Michigan 48197, United States
  • MNGI Digestive Health - Plymouth Endoscopy Center & Clinic
    Plymouth, Minnesota 55446, United States
  • Care Access Research LLC
    Jackson, Mississippi 39206, United States
  • Digestive Health Specialists
    Tupelo, Mississippi 38801, United States
  • Northwell Health
    Great Neck, New York 11021, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • University of North Carolina Center for Inflammatory Bowel Disease
    Chapel Hill, North Carolina 27599, United States
  • Carolina Digestive Diseases and Endoscopy Center
    Greenville, North Carolina 27834, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Care Access - Youngstown
    Poland, Ohio 44514, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Digestive Disease Associates
    Wyomissing, Pennsylvania 19610, United States
  • Midwest Medical Care
    Sioux Falls, South Dakota 57108, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Galen Medical Group
    Hixson, Tennessee 37343, United States
  • Digestive Health Associates of Texas
    Garland, Texas 75044, United States
  • Houston Methodist Research Ins
    Houston, Texas 77030, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Care Access Research LLC - Salt Lake City
    Ogden, Utah 84403, United States
  • Emeritas Research Group
    Leesburg, Virginia 20176, United States
  • The Gastroenterology Group, P.C.
    Reston, Virginia 20191, United States
  • Carilion Clinic
    Roanoke, Virginia 24016, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • Centro de Investigaciones Metabólicas (CINME)
    CABA, Buenos Aires C1027AAP, Argentina
  • Mautalen Salud e Investigacion-Centro de Osteopatías Médicas
    Ciudad Autonoma de Buenos Air, Buenos Aires C1128AAF, Argentina
  • CER Instituto Medico
    Quilmes, Buenos Aires B1878DVC, Argentina
  • Fundación de Estudios Clínicos
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Centro de Investigaciones Médicas Tucuman
    SAN M. de Tucuman, Tucumán Province T4000AXL, Argentina
  • C.I.C.E. 9 de Julio
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Hospital Privado Centro Medico de Cordoba SA
    Córdoba, X5016KEH, Argentina
  • Princess Alexandra Hospital
    Harlow, Essex CM20 1QX, Australia
  • Coastal Digestive Health
    Maroochydore, Queensland 4558, Australia
  • Mater University Hospital
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Box Hill Hospital Outpatients
    Box Hill, Victoria 3128, Australia
  • Melbourne Gastrointestinal Investigation Unit (MGIU)
    Malvern, Victoria 3144, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
  • Universitätsklinikum Salzburg
    Salzburg, 5020, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Universitair Ziekenhuis Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Centre Hospitalier de Wallonie Picarde - Site Notre Dame
    Tournai, Wallonne, Région 7500, Belgium
  • AZ Klina
    Brasschaat, 2930, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • West Edmonton Diabetes Center
    Edmonton, Alberta T5R 1W2, Canada
  • The Gordon and Leslie Diamond Health Care Centre
    Vancouver, British Columbia V5Z 1M9, Canada
  • GI Research Institute
    Vancouver, British Columbia V6Z 2K5, Canada
  • PerCuro Clinical Research
    Victoria, British Columbia V8V 3M9, Canada
  • Victoria Hospital
    London, Ontario N6A 4G5, Canada
  • University of Western Ontario
    London, Ontario N6A 5G1, Canada
  • Centre de santé et de services sociaux Champlain-Charles-Le Moyne
    Greenfield Park, Quebec J4V 2H1, Canada
  • Hopital Maisonneure-Rosemount
    Montreal, Quebec H1T 2M4, Canada
  • Inflammatory Bowel Disease Centre Montreal General Hospital - MUHC
    Montreal, Quebec H3G 1A4, Canada
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Xiangya Hospital Central South University
    Kaifu District, Changsha City 410008, China
  • The Affiliated 2nd Hosp. of Third Military Med. Univ. of PLA
    Chongqing, Chongqing Municipality 400037, China
  • The First Hospital Affiliated to AMU (Southwest Hospital)
    Chongqing, Chongqing Municipality 400038, China
  • The Sixth Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong 510655, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Affiliated Drum Tower Hospital of Nanjing University
    Nanjing, Jiangsu 210008, China
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu 210029, China
  • Nanjing Medical University - Nanjing Jiangning Hospital
    Nanjing, Jiangsu 211106, China
  • Jiangxi Pingxiang People's Hospital
    Pingxiang, Jiangxi 337055, China

Showing the first 100 of 385 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ran Z, Chen Y, Miao Y, Wang Y, Gao X, Zhong J, Ding X, Wang C, Zhang X, Ding Y, Hu N, Tang D, Yu J, Qian C, Shen J. Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. BioDrugs. 2026 Jul;40(4):733-745. doi: 10.1007/s40259-026-00776-y. Epub 2026 May 12. PubMed 42120652 ↗
  • Hart A, Navabi S, D'Haens G, Matsuoka K, Martin-Arranz MD, Atreya R, Samaan KH, Dhesi E, Redondo I, Zhu B, Paulissen J, Zaremba-Pechmann L, Baygani S, Limdi J, Laharie D, Danese S. Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis. United European Gastroenterol J. 2026 May;14(4):e70214. doi: 10.1002/ueg2.70214. PubMed 42104877 ↗
  • Clemow DB, Dubinsky MC, Baygani SK, Sands BE, Keohane A, Danese S, Schreiber S, Walsh AJ, Hibi T, Gibble TH, Moses RE, Travis SPL. Bowel urgency in ulcerative colitis: effect of baseline urgency and change in urgency in response to mirikizumab. J Patient Rep Outcomes. 2025 Jul 1;9(1):75. doi: 10.1186/s41687-025-00906-0. PubMed 40591171 ↗
  • Panaccione R, Chan-Diehl F, Baygani S, Fisher DA, Moses RE, Siegmund B, Walsh A, Kobayashi T, Dulai PS, Travis S. Fecal Calprotectin and C-Reactive Protein Association With Histologic and Endoscopic Endpoints in Mirikizumab-Treated Patients With Ulcerative Colitis. Crohns Colitis 360. 2025 Jun 14;7(2):otaf043. doi: 10.1093/crocol/otaf043. eCollection 2025 Apr. PubMed 40589947 ↗
  • Lee SD, Ehrlich AC, Pellanda P, Kaiser C, Todd K, Moses R, Walsh A. Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. Am J Gastroenterol. 2025 Dec 1;120(12):2857-2866. doi: 10.14309/ajg.0000000000003407. Epub 2025 Mar 12. PubMed 40071779 ↗
  • Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm Bowel Dis. 2025 Jul 7;31(7):1876-1890. doi: 10.1093/ibd/izae253. PubMed 39448057 ↗
  • Danese S, Dignass A, Matsuoka K, Ferrante M, Long M, Redondo I, Moses R, Maier S, Hunter Gibble T, Morris N, Milch C, Abreu MT. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. J Crohns Colitis. 2024 Nov 4;18(11):1845-1856. doi: 10.1093/ecco-jcc/jjae088. PubMed 38869019 ↗
  • Friedrich S, Chua L, Adams DH, Crandall W, Zhang XC. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies. Clin Pharmacol Ther. 2024 Aug;116(2):435-447. doi: 10.1002/cpt.3305. Epub 2024 May 26. PubMed 38797892 ↗
  • Long MD, Schreiber S, Hibi T, Gibble TH, Fisher DA, Park G, Moses RE, Higgins PDR, Lindsay JO, Lee SD, Escobar R, Jairath V. Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies. Crohns Colitis 360. 2024 Jan 6;6(1):otae001. doi: 10.1093/crocol/otae001. eCollection 2024 Jan. PubMed 38313767 ↗
  • Sands BE, Feagan BG, Hunter Gibble T, Traxler KA, Morris N, Eastman WJ, Schreiber S, Jairath V, Long MD, Armuzzi A. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies. Crohns Colitis 360. 2023 Nov 7;5(4):otad070. doi: 10.1093/crocol/otad070. eCollection 2023 Oct. PubMed 38034882 ↗
  • Chua L, Friedrich S, Zhang XC. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Clin Pharmacokinet. 2023 Oct;62(10):1479-1491. doi: 10.1007/s40262-023-01281-z. Epub 2023 Aug 23. PubMed 37610533 ↗
  • D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. PubMed 37379135 ↗
  • Magro F, Pai RK, Kobayashi T, Jairath V, Rieder F, Redondo I, Lissoos T, Morris N, Shan M, Park M, Peyrin-Biroulet L. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. J Crohns Colitis. 2023 Oct 20;17(9):1457-1470. doi: 10.1093/ecco-jcc/jjad050. PubMed 37057827 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Nov 2021, 36 months.

Results were first posted in Nov 2022, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 36 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2018
First posted
May 14, 2018
StartActual
Oct 19, 2018
Primary completionActual
Nov 3, 2021
CompletionActual
Feb 17, 2025
Results first posted
Nov 25, 2022
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03524092
Responsible party
Sponsor
First posted
May 14, 2018
Start date
Oct 19, 2018
Primary completion
Nov 3, 2021
Completion
Feb 17, 2025
Results posted
Nov 25, 2022
Last update
May 13, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion